篮球赔率

篮球赔率 Services FAQ Contact Us 0
Home Pharmaceuticals Immunoglobulin Market Size, Growth and Forecast to 2031
Immunoglobulin Market

Immunoglobulin Market Size, Share & Trends Analysis Report By Product (IgG, IgA, IgM, IgE, IgD), By Mode of Delivery (Intravenous Mode of Delivery, Subcutaneous Mode of Delivery), By Applications (Hypogammaglobulinemia, Chronic Inflammatory demyelinating polyneuropathy (CIDP), Immunodeficiency Disease, Myasthenia Gravis) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2022-2030

Report Code: SRPH3659DR
Author : 篮球赔率
Buy Now
File Formats

Table Of Content

  1. Executive Summary
    1. Research Objectives
    2. Limitations & Assumptions
    3. Market Scope & Segmentation
    4. Currency & Pricing Considered
    1. Emerging Regions / Countries
    2. Emerging Companies
    3. Emerging Applications / End Use
    1. Drivers
    2. Market Warning Factors
    3. Latest Macro Economic Indicators
    4. Geopolitical Impact
    5. Technology Factors
    1. Porters Five Forces Analysis
    2. Value Chain Analysis
    1. North America
    2. Europe
    3. APAC
    4. Middle East and Africa
    5. LATAM
  2. ESG Trends
    1. Global Immunoglobulin Market Introduction
    2. By Product
      1. Introduction
        1. Product By Value
      2. IgG
        1. By Value
      3. IgA
        1. By Value
      4. IgM
        1. By Value
      5. IgE
        1. By Value
      6. IgD
        1. By Value
    3. By Mode of Delivery
      1. Introduction
        1. Mode of Delivery By Value
      2. Intravenous Mode of Delivery
        1. By Value
      3. Subcutaneous Mode of Delivery
        1. By Value
    4. By Applications
      1. Introduction
        1. Applications By Value
      2. Hypogammaglobulinemia
        1. By Value
      3. Chronic Inflammatory demyelinating polyneuropathy (CIDP)
        1. By Value
      4. Immunodeficiency Disease
        1. By Value
      5. Myasthenia Gravis
        1. By Value
    1. Introduction
    2. By Product
      1. Introduction
        1. Product By Value
      2. IgG
        1. By Value
      3. IgA
        1. By Value
      4. IgM
        1. By Value
      5. IgE
        1. By Value
      6. IgD
        1. By Value
    3. By Mode of Delivery
      1. Introduction
        1. Mode of Delivery By Value
      2. Intravenous Mode of Delivery
        1. By Value
      3. Subcutaneous Mode of Delivery
        1. By Value
    4. By Applications
      1. Introduction
        1. Applications By Value
      2. Hypogammaglobulinemia
        1. By Value
      3. Chronic Inflammatory demyelinating polyneuropathy (CIDP)
        1. By Value
      4. Immunodeficiency Disease
        1. By Value
      5. Myasthenia Gravis
        1. By Value
    5. U.S.
      1. By Product
        1. Introduction
          1. Product By Value
        2. IgG
          1. By Value
        3. IgA
          1. By Value
        4. IgM
          1. By Value
        5. IgE
          1. By Value
        6. IgD
          1. By Value
      2. By Mode of Delivery
        1. Introduction
          1. Mode of Delivery By Value
        2. Intravenous Mode of Delivery
          1. By Value
        3. Subcutaneous Mode of Delivery
          1. By Value
      3. By Applications
        1. Introduction
          1. Applications By Value
        2. Hypogammaglobulinemia
          1. By Value
        3. Chronic Inflammatory demyelinating polyneuropathy (CIDP)
          1. By Value
        4. Immunodeficiency Disease
          1. By Value
        5. Myasthenia Gravis
          1. By Value
    6. Canada
    1. Introduction
    2. By Product
      1. Introduction
        1. Product By Value
      2. IgG
        1. By Value
      3. IgA
        1. By Value
      4. IgM
        1. By Value
      5. IgE
        1. By Value
      6. IgD
        1. By Value
    3. By Mode of Delivery
      1. Introduction
        1. Mode of Delivery By Value
      2. Intravenous Mode of Delivery
        1. By Value
      3. Subcutaneous Mode of Delivery
        1. By Value
    4. By Applications
      1. Introduction
        1. Applications By Value
      2. Hypogammaglobulinemia
        1. By Value
      3. Chronic Inflammatory demyelinating polyneuropathy (CIDP)
        1. By Value
      4. Immunodeficiency Disease
        1. By Value
      5. Myasthenia Gravis
        1. By Value
    5. U.K.
      1. By Product
        1. Introduction
          1. Product By Value
        2. IgG
          1. By Value
        3. IgA
          1. By Value
        4. IgM
          1. By Value
        5. IgE
          1. By Value
        6. IgD
          1. By Value
      2. By Mode of Delivery
        1. Introduction
          1. Mode of Delivery By Value
        2. Intravenous Mode of Delivery
          1. By Value
        3. Subcutaneous Mode of Delivery
          1. By Value
      3. By Applications
        1. Introduction
          1. Applications By Value
        2. Hypogammaglobulinemia
          1. By Value
        3. Chronic Inflammatory demyelinating polyneuropathy (CIDP)
          1. By Value
        4. Immunodeficiency Disease
          1. By Value
        5. Myasthenia Gravis
          1. By Value
    6. Germany
    7. France
    8. Spain
    9. Italy
    10. Russia
    11. Nordic
    12. Benelux
    13. Rest of Europe
    1. Introduction
    2. By Product
      1. Introduction
        1. Product By Value
      2. IgG
        1. By Value
      3. IgA
        1. By Value
      4. IgM
        1. By Value
      5. IgE
        1. By Value
      6. IgD
        1. By Value
    3. By Mode of Delivery
      1. Introduction
        1. Mode of Delivery By Value
      2. Intravenous Mode of Delivery
        1. By Value
      3. Subcutaneous Mode of Delivery
        1. By Value
    4. By Applications
      1. Introduction
        1. Applications By Value
      2. Hypogammaglobulinemia
        1. By Value
      3. Chronic Inflammatory demyelinating polyneuropathy (CIDP)
        1. By Value
      4. Immunodeficiency Disease
        1. By Value
      5. Myasthenia Gravis
        1. By Value
    5. China
      1. By Product
        1. Introduction
          1. Product By Value
        2. IgG
          1. By Value
        3. IgA
          1. By Value
        4. IgM
          1. By Value
        5. IgE
          1. By Value
        6. IgD
          1. By Value
      2. By Mode of Delivery
        1. Introduction
          1. Mode of Delivery By Value
        2. Intravenous Mode of Delivery
          1. By Value
        3. Subcutaneous Mode of Delivery
          1. By Value
      3. By Applications
        1. Introduction
          1. Applications By Value
        2. Hypogammaglobulinemia
          1. By Value
        3. Chronic Inflammatory demyelinating polyneuropathy (CIDP)
          1. By Value
        4. Immunodeficiency Disease
          1. By Value
        5. Myasthenia Gravis
          1. By Value
    6. Korea
    7. Japan
    8. India
    9. Australia
    10. Taiwan
    11. South East Asia
    12. Rest of Asia-Pacific
    1. Introduction
    2. By Product
      1. Introduction
        1. Product By Value
      2. IgG
        1. By Value
      3. IgA
        1. By Value
      4. IgM
        1. By Value
      5. IgE
        1. By Value
      6. IgD
        1. By Value
    3. By Mode of Delivery
      1. Introduction
        1. Mode of Delivery By Value
      2. Intravenous Mode of Delivery
        1. By Value
      3. Subcutaneous Mode of Delivery
        1. By Value
    4. By Applications
      1. Introduction
        1. Applications By Value
      2. Hypogammaglobulinemia
        1. By Value
      3. Chronic Inflammatory demyelinating polyneuropathy (CIDP)
        1. By Value
      4. Immunodeficiency Disease
        1. By Value
      5. Myasthenia Gravis
        1. By Value
    5. UAE
      1. By Product
        1. Introduction
          1. Product By Value
        2. IgG
          1. By Value
        3. IgA
          1. By Value
        4. IgM
          1. By Value
        5. IgE
          1. By Value
        6. IgD
          1. By Value
      2. By Mode of Delivery
        1. Introduction
          1. Mode of Delivery By Value
        2. Intravenous Mode of Delivery
          1. By Value
        3. Subcutaneous Mode of Delivery
          1. By Value
      3. By Applications
        1. Introduction
          1. Applications By Value
        2. Hypogammaglobulinemia
          1. By Value
        3. Chronic Inflammatory demyelinating polyneuropathy (CIDP)
          1. By Value
        4. Immunodeficiency Disease
          1. By Value
        5. Myasthenia Gravis
          1. By Value
    6. Turkey
    7. Saudi Arabia
    8. South Africa
    9. Egypt
    10. Nigeria
    11. Rest of MEA
    1. Introduction
    2. By Product
      1. Introduction
        1. Product By Value
      2. IgG
        1. By Value
      3. IgA
        1. By Value
      4. IgM
        1. By Value
      5. IgE
        1. By Value
      6. IgD
        1. By Value
    3. By Mode of Delivery
      1. Introduction
        1. Mode of Delivery By Value
      2. Intravenous Mode of Delivery
        1. By Value
      3. Subcutaneous Mode of Delivery
        1. By Value
    4. By Applications
      1. Introduction
        1. Applications By Value
      2. Hypogammaglobulinemia
        1. By Value
      3. Chronic Inflammatory demyelinating polyneuropathy (CIDP)
        1. By Value
      4. Immunodeficiency Disease
        1. By Value
      5. Myasthenia Gravis
        1. By Value
    5. Brazil
      1. By Product
        1. Introduction
          1. Product By Value
        2. IgG
          1. By Value
        3. IgA
          1. By Value
        4. IgM
          1. By Value
        5. IgE
          1. By Value
        6. IgD
          1. By Value
      2. By Mode of Delivery
        1. Introduction
          1. Mode of Delivery By Value
        2. Intravenous Mode of Delivery
          1. By Value
        3. Subcutaneous Mode of Delivery
          1. By Value
      3. By Applications
        1. Introduction
          1. Applications By Value
        2. Hypogammaglobulinemia
          1. By Value
        3. Chronic Inflammatory demyelinating polyneuropathy (CIDP)
          1. By Value
        4. Immunodeficiency Disease
          1. By Value
        5. Myasthenia Gravis
          1. By Value
    6. Mexico
    7. Argentina
    8. Chile
    9. Colombia
    10. Rest of LATAM
    1. Immunoglobulin Market Share By Players
    2. M&A Agreements & Collaboration Analysis
    1. Baxter International Inc.
      1. Overview
      2. Business Information
      3. Revenue
      4. ASP
      5. SWOT Analysis
      6. Recent Developments
    2. CSL Ltd
    3. Grifols SA
    4. Octapharma AG
    5. Kedrion Biopharma Inc.
    6. LFB group
    7. Biotest AG
    8. China Biologics Products Inc.
    9. Sichuan Yuanda Shuyang Pharmaceutical Co. Ltd
    10. Bayer Healthcare
    11. Takeda Pharmaceutical Company Limited
    12. Bio Products Laboratory
    13. Sanquin Plasma Products B.V.
    14. Evolve Biologics Inc.
    15. Pfizer Inc.
    16. Shanghai RAAS Blood Products Co. Ltd
    17. ADMA Biologics Inc.
    18. Johnson and Johnson
    1. Research Data
      1. Secondary Data
        1. Major secondary sources
        2. Key data from secondary sources
      2. Primary Data
        1. Key data from primary sources
        2. Breakdown of primaries
      3. Secondary And Primary Research
        1. Key industry insights
    2. Market Size Estimation
      1. Bottom-Up Approach
      2. Top-Down Approach
      3. Market Projection
    3. Research Assumptions
      1. Assumptions
    4. Limitations
    5. Risk Assessment
    1. Discussion Guide
    2. Customization Options
    3. Related Reports
  3. Disclaimer

Related Reports

Global Report
The global immunoglobulins market size was valued at USD 15.79 billion in 2022. It is estimated to reach USD 31.06 billion by 2031, growing at a CAGR of 7.81% during the forecast period (2023–2031). Immunoglobulins are antibodies produced by p
Buy Now
Global Report
The global intravenous immunoglobulin market size was valued at USD 11.17 billion in 2021. It is projected to reach USD 21.06 billion by 2030, growing at a CAGR of 7.3% during the forecast period (2022–2030). The antibodies produced by the imm
Buy Now

Purchase Benefits

  • Eligible for a free updated report next year
  • Completely customizable scope
  • 30% discount on your next purchase
  • Dedicated account manager
  • Query resolution within 24 hours
  • Permission to print the report

We are featured on :

篮球赔率
漏 Copyright . All rights Reserved.